ArQule Shares Rise

ArQule shares surged 44% on Thursday after the company said pre-clinical data on ARQ 531 in in diffuse large B-cell lymphoma demonstrated “potent” anti-tumor activity.

The company said the data support clinical trials with ARQ 531 in the ibrutinib resistant patient population. A phase 1 trial with ARQ 531 in patients with B-cell malignancies refractory to other therapeutic options, including ibrutinib, is planned to commence by the third quarter of 2017. Separately, the comapny said it will present data from the phase 1/2 trial in intrahepatic cholangiocarcinoma with fibroblast growth factor receptor inhibitor, ARQ 087, will be presented on at the ASCO annual meeting in Chicago, Illinois, in June.

Leave a Comment